Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
162 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Drug Addiction - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Pipeline Review, H2 2017, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape. Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 7, 7, 1, 29, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 5 molecules, respectively. Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Drug Addiction - Overview 7 Drug Addiction - Therapeutics Development 8 Pipeline Overview 8 Pipeline by Companies 9 Pipeline by Universities/Institutes 13 Products under Development by Companies 14 Products under Development by Universities/Institutes 17 Drug Addiction - Therapeutics Assessment 18 Assessment by Target 18 Assessment by Mechanism of Action 21 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Addiction - Companies Involved in Therapeutics Development 28 Addex Therapeutics Ltd 28 Aelis Farma SAS 28 Aphios Corp 29 BioCorRx Inc 29 Cerecor Inc 30 Chiesi Farmaceutici SpA 30 Curemark LLC 31 Egalet Corp 31 Embera NeuroTherapeutics Inc 32 F. Hoffmann-La Roche Ltd 32 Foresee Pharmaceuticals LLC 33 Heptares Therapeutics Ltd 33 Immunovaccine Inc 34 Indivior Plc 34 InterveXion Therapeutics LLC 35 Intra-Cellular Therapies Inc 35 Kyorin Pharmaceutical Co Ltd 36 Kyowa Hakko Kirin Co Ltd 36 Omeros Corp 37 Opiant Pharmaceuticals Inc 37 Orexigen Therapeutics Inc 38 P2D Bioscience 38 Saniona AB 39 Stada Arzneimittel AG 39 Teva Pharmaceutical Industries Ltd 40 Zynerba Pharmaceuticals Inc 40 Drug Addiction - Drug Profiles 41 (acetaminophen + hydrocodone bitartrate + Respiratory Drug) - Drug Profile 41 (hydrocodone bitartrate + naltrexone hydrochloride) - Drug Profile 42 (metyrapone + oxazepam) - Drug Profile 43 18-MC - Drug Profile 46 ADX-71441 - Drug Profile 48 ADX-71743 - Drug Profile 53 ADX-88178 - Drug Profile 54 AEF-0117 - Drug Profile 57 ANS-6637 - Drug Profile 58 AT-076 - Drug Profile 59 AT-089 - Drug Profile 60 AT-1001 - Drug Profile 61 AT-212 - Drug Profile 62 Biologic to Agonize TLR4 for Drug Addiction - Drug Profile 63 cannabidiol - Drug Profile 64 CERC-501 - Drug Profile 65 CM-1212 - Drug Profile 68 DDD-024 - Drug Profile 69 dronabinol - Drug Profile 70 dronabinol - Drug Profile 71 Drug for Addiction - Drug Profile 72 Enzyme for Cocaine Addiction - Drug Profile 73 EORA-101 - Drug Profile 74 EP-11313 - Drug Profile 75 FP-004 - Drug Profile 76 Gene Therapy to Activate Cocaine Hydrolase for Cocaine Abuse - Drug Profile 77 h-2E2 - Drug Profile 78 ibudilast - Drug Profile 79 istradefylline - Drug Profile 89 ITI-333 - Drug Profile 92 IXT-m200 - Drug Profile 93 JDTic - Drug Profile 96 JQ-1 - Drug Profile 97 KDAC-0001 - Drug Profile 98 levofacetoperane - Drug Profile 99 lofexidine hydrochloride - Drug Profile 100 MC-100093 - Drug Profile 103 naltrexone hydrochloride SR - Drug Profile 104 NLS-10 - Drug Profile 106 NS-2359 - Drug Profile 107 OMS-405 - Drug Profile 109 OMS-527 - Drug Profile 111 OPNT-001 - Drug Profile 113 OREX-1019 - Drug Profile 114 OREX-1038 - Drug Profile 115 oxycodone hydrochloride - Drug Profile 116 RBP-8000 - Drug Profile 118 Recombinant Enzyme for Cocaine Abuse - Drug Profile 120 RO-5256390 - Drug Profile 121 SERx-480 - Drug Profile 122 Small Molecule to Activate Kappa Opioid Receptor for CNS - Drug Profile 123 Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile 124 Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile 125 Small Molecules for Neonatal Abstinence Syndrome - Drug Profile 126 Small Molecules to Block VMAT2 for Methamphetamine Addiction - Drug Profile 127 Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile 128 Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 129 Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile 130 Small Molecules to Inhibit Kappa Opioid Receptor for CNS - Drug Profile 131 Small Molecules to Scavenge Free Radicals for Oxidative Stress Related Disorders - Drug Profile 132 Small Molecules to Target 5HT2 for CNS Disorders and Obesity - Drug Profile 133 Small Molecules to Target Nicotinic Acetylcholine Receptors for Drug Addiction and Drug Abuse - Drug Profile 134 Synthetic Peptide to Target Kappa Opioid Receptors for Drug Addiction - Drug Profile 135 Vaccine for Cocaine Addiction - Drug Profile 136 Vaccine for Drug Abuse - Drug Profile 137 Vaccine for Methamphetamine Abuse - Drug Profile 138 Vaccine for Methamphetamine Addiction - Drug Profile 139 VU-0463841 - Drug Profile 140 Drug Addiction - Dormant Projects 141 Drug Addiction - Discontinued Products 144 Drug Addiction - Product Development Milestones 145 Featured News & Press Releases 145 Appendix 156 Methodology 156 Coverage 156 Secondary Research 156 Primary Research 156 Expert Panel Validation 156 Contact Us 156 Disclaimer 157
List of Tables
Number of Products under Development for Drug Addiction, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Drug Addiction - Pipeline by Addex Therapeutics Ltd, H2 2017 Drug Addiction - Pipeline by Aelis Farma SAS, H2 2017 Drug Addiction - Pipeline by Aphios Corp, H2 2017 Drug Addiction - Pipeline by BioCorRx Inc, H2 2017 Drug Addiction - Pipeline by Cerecor Inc, H2 2017 Drug Addiction - Pipeline by Chiesi Farmaceutici SpA, H2 2017 Drug Addiction - Pipeline by Curemark LLC, H2 2017 Drug Addiction - Pipeline by Egalet Corp, H2 2017 Drug Addiction - Pipeline by Embera NeuroTherapeutics Inc, H2 2017 Drug Addiction - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 Drug Addiction - Pipeline by Foresee Pharmaceuticals LLC, H2 2017 Drug Addiction - Pipeline by Heptares Therapeutics Ltd, H2 2017 Drug Addiction - Pipeline by Immunovaccine Inc, H2 2017 Drug Addiction - Pipeline by Indivior Plc, H2 2017 Drug Addiction - Pipeline by InterveXion Therapeutics LLC, H2 2017 Drug Addiction - Pipeline by Intra-Cellular Therapies Inc, H2 2017 Drug Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017 Drug Addiction - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 Drug Addiction - Pipeline by Omeros Corp, H2 2017 Drug Addiction - Pipeline by Opiant Pharmaceuticals Inc, H2 2017 Drug Addiction - Pipeline by Orexigen Therapeutics Inc, H2 2017 Drug Addiction - Pipeline by P2D Bioscience, H2 2017 Drug Addiction - Pipeline by Saniona AB, H2 2017 Drug Addiction - Pipeline by Stada Arzneimittel AG, H2 2017 Drug Addiction - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017 Drug Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H2 2017 Drug Addiction - Dormant Projects, H2 2017 Drug Addiction - Dormant Projects, H2 2017 (Contd..1), H2 2017 Drug Addiction - Dormant Projects, H2 2017 (Contd..2), H2 2017 Drug Addiction - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
